Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan

doi:10.4239/wjd.v6.i1.136

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 1

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10807)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

537

WORD

299

HTML

4283

Figures (1-3)

240

Tables (1-1)

356

Sum=5715

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

760

Download

1745

Sum=2505

Publishing Process of This Article

Item

Count

Browse

1144

Download

1443

Sum=2587

Feb 15, 2015 (publication date) through Jul 16, 2024

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Feb 15, 2015; 6(1): 136-144
Published online Feb 15, 2015. doi: 10.4239/wjd.v6.i1.136

Full Size Figure Download Figure

Figure 1 Chemical structure of sodium-glucose cotransporter 2 inhibitors in late-stage clinical trials.

Citation: Ohkura T. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes 2015; 6(1): 136-144
URL: https://www.wjgnet.com/1948-9358/full/v6/i1/136.htm
DOI: https://dx.doi.org/10.4239/wjd.v6.i1.136